EVQLV and Libera Bio collaborate to develop and deliver novel antibodies to intracellular cancer targets
EVQLV Inc. and Libera Bio S.L. have signed a collaboration agreement to jointly address intracellular targets, some of the most elusive cancer targets that represent high unmet medical needs. Antibodies can be designed to address very specific targets along cancer pathways Many of the best-validated intracellular cancer targets have been deemed “undruggable” because large molecules cannot […]
Continue Reading